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While these comments may well apply to the inpatient
therapy of pneumonia with intravenous penicillin,
consideration also needs to be given to outpatient
treatment, which is commonly undertaken with oral agents_
Unfortunately, in this area there are as yet no published
studies or data on the possible efficacy of oral agents (such
as penicillin or amoxycillin) on which one could base firm
recommendations. Treatment failure with the emergence of
resistant strains has been described with several different
antibiotics.2!I It remains important to be aware of
susceptibility patterns in one's area, and to use appropriate
therapy based on those results.24,29
These recommendations are based on current knowledge_
It is essential for microbiology laboratories to test the
susceptibility of isolated pneumococci not only to penicillin
but to other antibiotics such as the cephalosporins.
Physicians treating patients with pneumonia need to be
aware of these results, not only to treat individual cases, but
to be familiar with trends in the community as a whole.
Changes in antibiotic susceptibility patterns in the future
may be a reason to modify the current recommendations.
Lastly, it may well be timeous to re-examine the use of the
pneumococcal vaccine for the prevention of pneumococcal
infections.J There is ongoing debate as to the efficacy of this
vaccine, especially in patients with co-morbid illness and/or
concomitant HIV infection that may predispose them to
infections with resistant pneumococci.J8 Currently available
vaccine preparations contain antigen that should provide
cover for most serotypes commonly associated with
penicillin resistance, and we would encourage more
widespread use of the vaccine, as has been suggested by
others. J These developments are also encouraging
investigators to develop pneumococcal conjugate vaccines
to improve the protective effect of the pneumococcal
vaccine, particularly in highly vulnerable paediatric
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Tuberculosis research
the way forward
Tuberculosis is back on the world stage with a vengeance,
perhaps at least partly as a consequence of complacency
about the threat it posed in the recent past. A number of
historical sources have documented that much of the
currently developed world was, in the past, subject to an
epidemic of tuberculosis that ran its course over a period of
several centuries. 1,2 It seems likely that one of the main
causes of this epidemic was the process of urbanisation and
industrialisation, the accompanying stresses and strains
imposed by overcrowding, unemployment and the
associated social disruption. Long before the availability of
chemotherapy rt was apparent that the mortality associated
with the tuberculosis epidemic was declining. In the opinion
of some researchers this decline also antedated any
improvement in the precipitating poor socio-economic
factors. suggesting that the elimination of susceptible
individuals had created a population with increased
resistance to tuberculosis_ On its introduction into a
susceptible population, tuberculosis spreads rapidly and
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affects predominantly younger individuals and
characteristically more females than males. The course of
the disease is acute in individuals from a susceptible
population and, left untreated. IT has a high mortality rate.
The destructive effects of tuberculosis among black and
coloured African troops in both world wars are well known.3-"
Other features of an epidemic are the absence of clearly
identifiable high-risk groupsS and a high annual risk of
infection, with the majority of the population becoming
tUberculin-positive at a relatiVely young age.' Such features
were well documented in several populations during the last
century.' As the epidemic wanes, the clinical features of
disease become less florid and it tends to affect mainly
older, predominantly male. individuals.
In an embarrassing reversal of the previous long-term
decline in the incidence of tuberculosis, a number of relatively
affluent developed nations have recently experienced an
increased incidence of tuberCUlosis. This is at least partly due
to HIV. Unfortunately. many parts of the developing world still
experience tuberculosis in epidemic proportions, and the
disease is a· major cause of morbidity and mortality - to such
an extent that the WHO recently took the unprecedented step
of declaring tuberculosis a global emergency. Approximately
one-third of the world population has been infected with the
bacillus and the combination of a high incidence of
tuberculosis and HIV infection is already wreaking havoc in
some developing countries. .
At present, vaccination often appears to be of
questionable benefit and cannot prevent infection. The key
to the control of tuberculosis remains the efficient detection
and treatment of smear-positive cases, even within a well-
managed national control programme. However. because
the chemotherapeutic regimen is protracted, compliance
may be problematic and health workers will require the long-
term enthusiastic support of the community. There is also
the disconcerting emergence of muttidrug-resistant
organisms. These considerations necessitate the search for
novel drugs and vaccines, and a better knowledge of the
pathogenesis of the disease is a prerequisite for this. These
goals are being actively pursued In South Africa. the UK and
Canada by the Glaxo-Wellcome Action TB initiative. The
prime motivation for this effort is to discover an entirely new
antituberculosis agent. Recognising that there tends to be
an inverse relationship between feasibility and novelty, the
research initiative has elements that range from community
and systems research to besic molecular biology. Some of
the necent work, particularily in the latter category, is
highlighted below.
In many deVeloping countries, including South Africa, little
information is available on the burden and spread of this
disease. One of the advances that will aid the
epidemiological study of tuberculosis Is the discovery that
an insertion element found in the genome of Mycobacterium
tuberculosis may be present In different locations and at
variable copy numbers.' This has made it possible to
genotype (DNA fingerprint) any culture of the organism
accurately, and has introduced the new study of molecular
epidemiology. Rngerprinting studies show that essentially
one strain of bacteria resides within a given patient at one
time. This apparent strain dominance is not understood. but
even in high-incidence communities it may potentially be
used to trace the routes of transmission in a community.
Even under the apparent blanket of an epidemic, it may
EDITORIAL
prove possible to identify high-risk groups precisely for
better targeting of the approach to tuberculosis control.
Given the high incidence of tuberculosis in some South
African communities, which may exceed 1 000/100 000 per
annum, one might expect little strain diversity; this is
evidence of a high degree of contact and recent
transmission. Surprisingly, in communities as diverse as an
urban, low HIV incidence community (Cape Town) and a
high HIV incidence rural community in Kwazulu-Natal. strain
diversity is high. This result is unexpected, given similar
surveys done elsewhere. Such studies will help to address
questions about the role of exogenous reinfection and
endogenous reactivation and will allow assessment of
efficacy of treatment in a community. It will also aid the
fonnulation of strategies to combat the disease by
identifying sources and routes taken as disease spreads, as
has been done in other urban centres.' In this regard, the
establishment of a unifonn, national strain database could
be an extremely valuable and desirable future objective.
A tuberculosis strain database may be of considerable
importance in view of the association between tuberculosis
and HIV with regard to spread (e.g. via long-distance
transport routes) and chemoprophylaxis. Recent results, for
example. show that over half of the drug-resistant cases of
tuberculosis detected in a high-incidence community in
Cape Town are probably the result of recent transmission of
drug-resistant strains, and not due to the deVelopment of
drug resistance in an existing strain. Further studies on the
genome are likely to identify other markers10 which may be
useful in these studies.
The key to unraVelling the pathogenesis of tuberculosis lies
in understanding the balance between the virulence
determinants of M. tuberculosis and the host immune
response. These are two sides of the same coin, and the one
cannot be understood WIThout the other. The pathogen
displays prodigious capacities for invasion and long-term
persistence in host cells and tissues. On the other hand, the
human host is well equipped to suppress, in the great majority
of cases, an M. tuberculosis infection and to prevent
progression to active disease. This interplay between organism
and host depends on the genetics, cell wall components.
metabolism and secreted factors of the bacterium, its
adhesion to and uptake by host cells, killing mechanisms or
intraceUular survival and donnancy, antigen presentation and
specific T-eeU responses. Given this background, more
research effort is needed to unravel these processes.
Molecular genetic approaches are being used to study
genes encoding specific mycobacterial proteins that may be
involved in the virulence, immunopathology or drug
resistance of M. tuberculosis. The evaluation of potential
dnug targets is dependent on the availability of efficient
methods for specifically creating mutations in candidate
genes and anatysing their effects on the organism in vivo.
Therefore, several targeted mutagenesis approaches have
been investigated. Gene replacement has been successfully
achieved in some of the mycobacteria and the methodology
is currently being developed further for application in M.
tuberculosis. In the light of these and other significant
advances around the world in the dev~opmentof alternative
specific 'gene knockouts' and random mutagenesis
methodologies,l1·12 the possibility of readily generating
mutants of pathogenic mycobacteria for virulence screening
may soon become a reality. The pathogenic mycobacteria
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have obviously evolved mechanisms for ensuring their
survrval in the intracellular phagocytic host cell environment.
Since a major component of the killing mechanism
employed by macrophages involves the production of DNA-
damaging agents during the oxidative burst of these cells, it
is likely that the existence of efficient DNA repair
mechanisms is central to the survival strategy adopted by
the pathogenic mycobacteria in vivo.13 Several mycobacterial
enzymes involved in DNA repair are being analysed via a
combination of genetic, biochemical and physiological
approaches. The genes encoding the repair enzyme DNA
polymerase I (Poll) from M. tuberculosis and M. smegmafis
have been cloned, and the M. tuberculosis enzyme has been
enzymatically analysed." In addition, significant progress
has been made in probing the role of mycobacterial Poll in
vivo by analysis of the phenotype of a polymerase-deficient
mutant of M. smegmafis that was constructed by targeted
gene replacement. Another enzyme implicated in the
mechanism of recovery from DNA damage, ribonuclease
(RNase) HI, has been analysed with a similar integrated
approach.l !> The mechanisms underlying the regulation of
RNase HI levels in mycobacteria that have sustained DNA
damage are currently under investigation. The response of
mycobacteria to damage induced by alkylating agents is
also under investigation within the initiative. The presence of
alkylation repair (Ada) activity has been demonstrated in
mycobacteria. The Ada gene from M. tuberculosis has been
cloned and partialiy sequenced, and was found to be
significantly homologous to the corresponding gene from
Escherichia coli. In addition to this repair enzyme, other
enzymes may protect the mycobacterial genome from DNA-
damaging agents. One candidate enzyme is the dual-
function catalase/peroxidase, KatG. This enzyme inactivates
reactive oxygen radicals. Studies indicate that the enzyme
may have additional activities - for example, mutations in
the gene can lead to isoniazjd resistance.
Related studies have focused on the ability of
mycobacteria to cope with changes in environmental
conditions, such as temperature and nutrient deprivation,
since rt is likely that the ability of M. tuberculosis to counter
such challenges successfully is inextricably linked to its
ability to persist in macrophages and granulomatous
caseous lesions. Significant emphasis is therefore being
placed on the understanding of the regulatory networks
governing gene expression under a variety of growth
conditions of this organism.
The emergence of drug-resistant organisms is cause for
concern and has led to research linked to understanding this
process. For example, attempts are being made to elucidate
the mode of action of pyrazinamide and the molecular basis
of pyrazinamide resistance in M. tuberculosis. It is thought
that the pyrazinamide is converted by a pyrazinamidase
enzyme to pyrazinoic acid, which is lethal to M. tuberculosis.
A pyrazinamidase from E. coli has been purified and
characterised and stUdies aimed at identifying a
mycobacterial homologue are currently under way. rt has
been shown that the products of the katG, inhA, rpoB and
rpsL and 16srRNA genes are involved in resistance to
isoniazid, rifampicin and streptomycin, respectively.
However, aberrations in these genes do not account for all
cases of resistance11 and other mechanisms are being
sought. Work is under way to investigate the feasibility of a
rapid test for rifampicin resistance, since rt has been shown
that this is indicated by mutations in rpoB in nearly all cases.
This could be a useful test, since the work also shows that
approximately 95% of rifampicin-resistant samples are also
isoniazid-resistant.
A key virulence determinant of M. tuberculosis is its
invasiveness. The bacillus rapidly invades host monocytes
and macrophages and freely grows and replicates in these
cells, despite the fact that macrophages are a central
component of the host immune system. We now know that
the organism binds to specific macrophage receptors17 and
that this binding is both opsonic [I.e. it depends on serum
proteins such as complement) and non-opsonic. Work within
Action TB has established conditions under which non-
opsonic binding can occur, and this probably depends on
specific molecules (ligands) on the surface of the bacteria.,a
This offers the prospect of designing antagonists that can
block the critical first step of attachment to the host cell.
After attachment, the organism invades the macrophage
and takes up long-term residence in the face of formidable
defences. It accomplishes this by blocking the nonnal
processing of ingested particles.'9 In addition to disabling
these innate macrophage defences, M. tuberculosis also
interrupts the ability of the macrophage to signal to patrolling
Iymphocytes that it is infected, thereby reducing the
effectiveness of specific, acquired immunity.20 Lymphocytes,
which confer acqUired immunity, inspect cells in tissues,
including macrophages, for the presence of pathogen-derived
molecules (Le. antigens) on their surfaces. As well as
interfering with antigen processing and presentation by the
macrophage, M. tuberculosis may also reduce the ability of
infected macrophages to respond appropriataly to T
Iymphocytes that have detected the infection, as indicated by
preliminary work within the initiative.
Notwithstanding the impressive virulence strategies of M.
tuberculosis, the human host is, as stated earlier, quite
capable of successfully suppressing an infection in most
instances. This depends on both innate (pre-immune)
defences cmd specific, acquired immunity. The former
involves the macrophage defences already alluded to, as
well as the activation of natural killer (NK) cells by
macrophages and vice versa. The extent to which
macrophages can control intracellular pathogens depends
on the state of readiness or 'priming' of the macrophage. In
the mouse there is clear evidence that this priming is
genetically determined.21 In humans this is controversial, but
Action TB is actively addressing this question through the
use of a molecular genetics approach in accurately defined,
high-incidence communities. Work has been inmated on
some candidate genes for disease susceptibility, such as
Nramp," TNF and HLA; a whole-iJenome search may
become a reality in the future.
Acquired immunity, on the other hand, depends on T
Iymphocytes directed against specific antigens of M.
tuberculosis. There is increasing evidence that not only
CD4+, but also CD8+, cells contribute to the specific
immune response to M. tuberculosis.=' These Iymphocytes
can produce large amounts of cylokines which activate
macrophages, NK cells and also the Iymphocytes
themselves.~ Certain cylokines (specifically IL-4, IL-10 and
TFG-~), however, suppress the cell-mediated immune
response and rt is of great interest to determine the exact
mechanisms determining the choice of cytokine secretion.2-o'
Another function of T cells is to kill cells infected with M.
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tuberculosis. The jury is still out on whether the killing of
infected macrophages by cytotoxic cells contributes to the
actual killing of tubercle bacilli.
It is hoped that the elucidation of M. tuberculosis virulence
factors and the components of the host defence that are
critical for protection will provide novel targets for the
rational design of unconventional drugs, the development of
an effective vaccine and the application of hitherto untried
immunological interventions.
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South Africa - time for a
new paradigm?
Globally, the World Health Organisation (WHO) estimates
that about 8 million new cases of tuberculosis occur, and
that there are about 3 million deaths from tuberculosis, each
year.' The situation is so grave that the WHO has declared
tuberculosis to be a global public health emergency.2 With
the current HIV pandemic, the tuberculosis situation (in
Africa in particular) is very serious; case rates have doubled
in some African countries.3 In central Africa more than 70%
of adults WITh tuberculosis may be HIV-positive.4
South Africa's tuberculosis problem reflects that of the
global community. More cases of tuberculosis than of any
other disease are reported annually in South Africa. There
were about 82 500 cases in 1992, with an overall incidence
rate of about 250/100 000 population' The basic
epidemiology of tuberculosis in South Africa is well
described; for example, incidence rates are highest in the
coloured population in the Western Cape (700/100 000)'
South Africa is suffering an explosive HIV epidemic, with
Kwazulu-Natal hardest hi1! At Hlabisa Hospital, a typical rural
district hospital in the northern part of the province, 35% of
adutts diagnosed with tuberculosis in mid-1993 were HIV-
positive.' (The HIV seroprevalence in women attending
antenatal clinics in Hlabisa district was 7.9% at that time").
The tuberculosis case load at Hlabisa has increased
dramatically in recent years (Fig. 1). While some of this
increase reflects a higher general workload from improved
staffing, referral in from neighbouring districts and the impact
of a more 'user-friendly' service, the impact of HIV infection
and the worsening poverty in the area probably account for
the rest. It is clearly very difficutt for any service to cope with
a 300% increase in workload at a time of major political and
health service transition and no increase in resources.
Tuberculosis control is, in theory, simple and highly cost-
effeCtive. Passive case-finding and the provision of short-
course (6-month) chemotherapy will cure the vast majority of
cases and, if coverage is high enough, will lead to a
sustained reduction in case rates. This is the basic strategy
advocated by the WHO and the International Union against
Tuberculosis and Lung Disease (IUATLD)." Why then has
this strategy failed on a global level? Why is tuberculosis a
global public health emergency? The reasons are many and
well documented," That it can be effective, as seen in
Tanzania for example, is encouraging.12 The failure to control
tuberculosis in this country in large part reflects the
apartheid legacy of poverty, discrimination and
fragmentation of health services. But what now? Should
South Africa follow the conventional WHO/IUATLD path, or
could an a1temative approach yield beller resu~s?
We would advocate a change in the way that tuberculosis
control is both viewed and implemented (Table I).
What justifications for these proposals exist in the world
literature? Intermittent therapy for tuberculosis has long
been known to be at least as effective as daily treatment.'3
It was first used in the very early days of chemotherapy for
tuberculosis when large numbers of patients had to be
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